Alnylam Pharmaceuticals, Inc.
ALNY
주식 순위
#787
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily... Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
주가
$230.76
마지막 동기화: 2026-10-20
시가총액
$30.88B
변동 (1일)
-1.08%
변동 (1년)
-51.32%
국가
US
거래 Alnylam Pharmaceuticals, Inc. (ALNY)
카테고리
Healthcare
Alnylam Pharmaceuticals, Inc. (ALNY)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 36.80
Alnylam Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 36.80입니다. 2023년 말 기준 P/E 비율은 -54.31였습니다.
Alnylam Pharmaceuticals, Inc.의 P/E 비율 기록 (2002 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 36.80 | -134.08% |
| 2024 | -107.99 | 98.85% |
| 2023 | -54.31 | 112.42% |
| 2022 | -25.57 | 8.55% |
| 2021 | -23.55 | 35.27% |
| 2020 | -17.41 | 22.61% |
| 2019 | -14.20 | 47.45% |
| 2018 | -9.63 | -58.91% |
| 2017 | -23.44 | 199.93% |
| 2016 | -7.81 | -71.33% |
| 2015 | -27.26 | 36.35% |
| 2014 | -19.99 | -54.93% |
| 2013 | -44.36 | 412.40% |
| 2012 | -8.66 | 44.38% |
| 2011 | -6.00 | -37.06% |
| 2010 | -9.53 | -38.20% |
| 2009 | -15.41 | -60.17% |
| 2008 | -38.70 | 194.23% |
| 2007 | -13.15 | -33.30% |
| 2006 | -19.72 | 188.58% |
| 2005 | -6.83 | 151.30% |
| 2004 | -2.72 | 1,101.55% |
| 2003 | -0.23 | -53.00% |
| 2002 | -0.48 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -21.79% |
US
|
|
| -28.36 | -177.06% |
US
|
|
| -24.57 | -166.76% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -17.58% |
NL
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.